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During the first two years’ follow-up, hospital admissions were significantly lower 
in controls (p< 0.0001 vs PAP for both years); number of admissions was 5,323 in 
the control group and 6,931 in the PAP group. Conversely, in year 3 of follow-up, the 
number of inpatient treatments was significantly lower in the PAP vs control group 
(1,525 vs 2,000; p< 0.0001). Total cost of illness was higher in the PAP group compared 
with controls (year 1: € 6,704 vs € 5,015 [p< 0.0001]; year 2: € 5,272 vs € 4,901 [p< 0.001]; 
year 3: € 5,091 vs € 4,830 [p< 0.001]). Recipients of PAP therapy had a significantly 
lower 3-year mortality rate compared with controls (4.5% vs 7.2%; p< 0.0001; rela-
tive risk reduction 37.5%). ConClusions: SA patients with PAP therapy showed a 
significantly reduced mortality and morbidity. Also, the data showed that treatment 
may begin to have beneficial effects on the hospitalisation rate after 2 years of treat-
ment. Costs of PAP remained higher than control over the first 3 years of therapy, 
although the difference between treatment groups reduced over time. A follow-up 
period of ≥ 5 years may be required to show beneficial economic outcomes in SA 
patients receiving PAP therapy.
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objeCtives: To characterize psychiatric health care utilization and its related costs in 
a cohort of newly diagnosed ASD individuals. Methods: A cohort was built using the 
provincial public health care insurance program (RAMQ) databases. Newly diagnosed 
subjects with ASD were selected (≥ 2 diagnoses (separate dates) with ICD-9 codes: 
299.X, excluding 299.2) between January 1998 and December 2010. Cohort entry was 
the date of first diagnosis confirmed by the absence of ASD diagnosis in previous 5 
years. Participants aged ≥ 26 years or those not covered by the RAMQ drug plan in the 
year preceding cohort entry were excluded. Demographic and clinical patient charac-
teristics were done at cohort entry. Health care utilisation associated with a psychi-
atric diagnosis (physician and emergency room visits, hospitalisations), psychoactive 
drug use (anticonvulsants, antipsychotics, antidepressants, anxiolytics, ADHD drugs) 
and total cumulative costs were assessed across 5 years of follow-up. Results: A 
number of 1227 patients among the total cohort had 5 years of follow-up (male: 80.3%; 
median age: 7 years). In the 1-year following diagnosis, the mean number of visits to 
general practitioners was 1.6 whereas psychiatry related visits to specialists were 7.2 
which decreased over time. Psychoactive drug utilisation was initially present in 49.3% 
of participants, and increased to 53.2% at 5 years. The psychiatric hospitalization rate 
was 10.4% in the 1-year of follow-up with the highest rates seen in adolescents (20%) 
and young adults (24%). Cumulative costs of psychiatric health services and psycho-
active drugs at 1-year of follow-up were $547,568CAD and $600,433CAD, respectively. 
Those costs were at $216,827CAD and $934,381CAD at 5-years. ConClusions: While 
cost related to psychiatric health care services decreased by more than half in the 5 
years of follow-up, drug costs rose by 56%. Access to long term care and monitoring 
among the ASD population is discussed.
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objeCtives: Endometriosis takes the third place in the structure of the gyneco-
logical pathology after inflammatory diseases of the female genital organs and 
uterine fibroids. Endometriosis is most commonly diagnosed in women between 
30 and 40 years of age - reproductive and functional age. The aim of the study was 
to calculate the average cost of hormonal therapy of endometriosis in Ukraine for 
a minimum period of 6 months, considering that the main aim of this therapy 
is the elimination of two major problems such as endometriosis-associated pain 
(dysmenorrhea, dyspareunia, chronic pelvic pain, ovulation-related pain, dysche-
zia) and infertility. Methods: We analyzed the cost of treatment hormones per 
patient for course. We used the real data from medical records of patients who were 
treated in a regional perinatal center in Lviv. We have analyzed almost 150 stories 
diseases for 2012-2013. We used the prices from Ukrainian database of Morion com-
pany (Kiev) on 01.01.2014 (1 USD = 8,24 UAH). Results: In Ukraine for treatment 
of endometriosis often use these three alternative treatment hormonal schemes. 
We calculated the costs for course per patient in 6 months duration. The treatment 
costs are Dydrogesterone (tab. 10 mg №20) - 345 USD (2843 UAH); Dienogest (tab. 2 mg 
№28) - 550 USD (4530 UAH); Triptorelin (powder for susp. for injection 3,75 mg) - 1347 
USD (11097 UAH). ConClusions: The alternative hormonal treatment schemes of 
endometriosis are differences 4 times per 1 patient for 6 months duration. Almost 
patient fully pay costs out of pocket, through this treatment costs are quite high for 
Ukrainian women. These results support the need to provide some state funding 
for the treatment of endometriosis and introduction the reimbursement system for 
hormonal medicine in Ukraine.
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objeCtives: To review the cost-effectiveness literature evaluating positron emis-
sion tomography (PET) imaging. Methods: We systematically searched the PubMed 
database and the Tufts Medical Center Cost-Effectiveness Analysis Registry to 
identify studies evaluating the economics of PET imaging. We categorized each 
study with respect to indication, i.e., cardiology, neurology, oncology, and other. 
We extracted data pertaining to: the date of publication; the region in which the 
significantly (p< 0.01) higher rates of outpatient visits, ambulatory surgical center 
visits, physical therapy visits, anti-depressant use and ED prescription use com-
pared to controls. Compared with their controls, Medicare PD patients had on 
average significantly higher risk-adjusted all-cause outpatient costs ($5,322 vs. 
$3,162) and annual all-inclusive health care costs ($10,675 vs. $7,926); risk-adjusted 
annual total all-cause costs for the commercial cohort were $10,463 vs. $5,918 (all 
p< 0.0001). ConClusions: PD patients had higher comorbidity rates, utilization, 
and annual total costs compared with matched controls.
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objeCtives: Hospital costs for newborns are indirectly associated with gestational 
age (GA) at birth. The higher costs of prematurity are primarily a function of the 
presence of clusters of comorbidities. The objective of this study was to explore 
the incremental costs associated with having neonatal comorbidities of prematu-
rity, and whether stable cost estimates can be derived for use in economic evalua-
tions. Methods: Our analyses included 4292 hospital records from infants (23-37 
wks GA) born to mothers with uncomplicated singleton pregnancies in spontane-
ous preterm labor at the Medical University of South Carolina from 2001-2010 . 
Thirteen comorbidities associated with prematurity were identified: respiratory 
distress syndrome (RDS), bronchopulmonary dysplasia (BPD), sepsis, meningitis, 
necrotizing enterocolitis (NEC), intraventricular hemorrhage I & II and III & IV (IVH 
I/II & IVH III/IV), periventricular leukomalacia (PVL), anemia, apnea, retinopathy 
of prematurity requiring surgery (ROP), convulsions, and brain injury (PVL/CPV). 
To estimate incremental cost of each, adjusted for other comorbidities and GA, 
we transformed the data and implemented a partial least squares model, with 10 
fold-cross validation of the full model. Results: Transformation of the data and 
implementation of the partial least squares model eliminated collinearity issues 
in the data leading to stable incremental cost estimates, Q2= 0.69. The model was 
found to be stable under bootstrapping. Cost outliers were retained in the model as 
the incremental costs estimates were stable and the model had good predictability 
when they were retained. Incremental costs ranged from $23,121 (ROP) to $4,529 
(convulsions). ConClusions: In addition to GA at birth, these 13 comorbidities of 
prematurity impact total hospital costs of premature infants. This study provides 
reliable estimates of the incremental cost associated with comorbidities of prema-
turity, controlling for GA at birth, to be used in future economic analyses of the cost 
associated with premature birth due to spontaneous preterm labor.
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objeCtives: To estimate the economic burden of unintended pregnancy in the 
perspective of public payer and the impact of UP on related public health meas-
ures in Brazil. Methods: A decision-analysis cost model was constructed based 
on pregnancy rates, probabilities and costs of pregnancy and neonatal outcomes 
(miscarriage, induced abortion, and live birth) in Brazil. The model took account of 
both maternal and child outcomes, and accounted for health care costs related with 
preterm birth, neonatal admission, cerebral palsy, neonatal and maternal mortality. 
All costs are reported as Real$ (Brazilian currency). Results: In Brazil there were 1.8 
million unintended pregnancies in 2010. Those unintended pregnancies resulted in 
159,151 miscarriages, 48,769 induced abortions, and 1.58 million live births. It was 
estimated there were 312 maternal deaths. The number of infant deaths within the 
12-months following birth was estimated at 32,864. The total health care costs to 
public payer attributed to unintended pregnancies are estimated to be R$4.1 billion 
in one year of which R$4.07 billion (99.2%) attributed to births and resulting com-
plications and R$32 million (0.8%) was attributed to miscarriage. The average cost 
per UP was R$2,293. ConClusions: Unintended pregnancies impose substantial 
burden on the Brazilian society in term of health care costs, infant and maternal 
morbidity and mortality. Reduction in UPs will not only generate substantial cost-
savings, but also improve public health profile of the country. Public policymakers 
should allocate budget on cost-effective pregnancy prevention interventions to 
address this issue.
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objeCtives: Sleep apnea (SA) is relatively common, occurring in about 2–4% of the 
general population. This study investigated the effects of PAP therapy on morbidity 
(including comorbid disease), all-cause mortality, and costs in patients with SA. 
A statutory health insurance (SHI) perspective was taken. Methods: A total of 
approx. 4 million individuals covered by the SHI database were analysed (ca. 5% of 
the German SHI population). PAP therapy was initiated in 4068 patients with SA. 
Propensity score was used to define a control group of 4068 SA patients matched 
for age, sex, risk factors/etiology, region and medication who received usual care 
(no PAP). Patients were followed after therapy initiation over three years. Results: 
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objeCtives: Novel specialty biopharmaceuticals hold great promise for patients 
living with complex and chronic conditions. However, high research and develop-
ment costs, special handling, and other necessary enhancements to patient support 
programs all contribute to frequently higher prices for these products. This study 
sought to assess the value of specialty pharmaceuticals through an examination of 
the clinical, functional, and economic benefits of these treatments for the top three 
disease areas by pharmaceutical spend: rheumatoid arthritis (RA), multiple sclerosis 
(MS), and breast cancer (BC). Methods: A systematic review of market research and 
cost-effectiveness articles was conducted for each disease area to assess clinical, 
functional, and economic outcomes associated with specialty medicine treatments 
versus the previous standard of care. Results: All RA clinical (ACR) and functional 
(HAQ) outcome articles were classified as positive. The median cost-effectiveness 
ratio was $37,000 per QALY. All MS clinical outcome (relapse rate) articles were posi-
tive. The MS functional outcome (EDSS) findings were less conclusive. The median 
cost-effectiveness ratio was $220,000 per QALY. The majority of BC articles yielded 
statistically inconclusive results for survival. All functional outcome (QLQ-C30) arti-
cles were positive. The median cost-effectiveness ratio was $49,000 per QALY. All 
endpoints reflect a population average treatment response and did not account for 
the presence of patient heterogeneity of treatment effect. ConClusions: Novel 
specialty therapies hold great promise for arresting disease progression and improv-
ing quality of life for the three conditions associated with the highest specialty 
pharmaceutical spending. These findings demonstrate a strong value proposition 
for specialty pharmaceuticals in general, and suggest even greater substantial 
potential individual patient benefit with consideration of patient heterogeneity.
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bACkgRound: Herpes Zoster (HZ) or shingles, common among elderly people, 
increases with age and so does its severe outcomes including post herpetic neuralgia 
(PHN). Although efficacious in immunocompetent adults aged ≥ 50 years, protection 
from a licensed vaccine decreases in time which, faced with increasing disease risks, 
makes age of vaccination crucial. objeCtives: To evaluate the cost effectiveness 
of HZ vaccination among adults aged ≥ 50 years and identify the public health and 
economically optimal vaccination age. Methods: We used a cohort-based decision 
analysis model to compare the age-specific incidence, health care resource utiliza-
tion, costs and quality-adjusted life years (QALYs) related to HZ, PHN and non-pain 
complications among unvaccinated and vaccinated individuals at either age 50, 60 
or 70 years. Health outcomes, resource utilization and costs were projected for the 
US cohorts from 50 to 99 years of age. It incorporates HZ-specific QALY scores for 
duration and intensity of pain and the probabilities for Monte Carlo simulations. 
QALYs gained and cost per QALY gained from vaccination are the primary estimates. 
Sensitivity analyses were conducted on vaccine efficacy duration and other vari-
ables. Results: Vaccinating at age 60 would prevent more shingles cases (26,147 
cases per million persons) followed by vaccinating at age 70 while vaccinating at 
age 50 prevents the less number of shingles cases (21,269 vs. 19,795 respectively). 
However, vaccinating at age 70 would be the strategy with the biggest impact (8,055 
PHN cases prevented), followed by age 60 and then age 50 (4,055 vs. 1,012 PHN cases 
prevented, respectively). Vaccinating at age 70, 60, and 50 would societally cost 
$38,000, $80,000 and $272,000 per QALY saved, respectively. ConClusions: Overall, 
the optimal age for vaccination would be at 70 years. While various uncertainties 
remain, our results were robust based on the sensitivity analyses and the magnitude 
of the differences in outcomes and costs between strategies.
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objeCtives: To conduct an economic evaluation comparing a recombinant gonado-
trophin (r-hFSH, follitropin alfa, GONAL-f) with two classes of urinary gonadotro-
phins, hp-HMG (Menopur) and u-FSH (Fostimon) for ovarian stimulation in women 
undergoing in-vitro fertilization (IVF) treatment in The Netherlands Methods: A 
pharmaco-economic model was developed, simulating each step in IVF protocol 
from start of therapy until either live birth, new IVF treatment cycle, or stopping 
IVF, following a long down-regulation protocol. A decision tree combined with a 
Markov model details progress through each health state, including oocyte retrieval, 
fresh embryo transfer, up to two subsequent cryo-embryo transfers, and (ongoing) 
pregnancy or miscarriage. A health insurer perspective was chosen and the time 
horizon was set to a maximum of three consecutive treatment cycles. Transition 
probabilities and costing data were derived from a real-world observational out-
comes database (Germany), and official tariff lists (The Netherlands). Adverse events 
were considered equal amongst comparators and therefore excluded. The model 
was validated by clinical experts to ensure appropriateness and to local manage-
ment of infertility and applicability. A Monte Carlo simulation with 5,000 iterations 
was undertaken for each strategy to explore uncertainty and to construct uncer-
tainty intervals (UI). Results: Mean total treatment costs were estimated as: € 5,664 
for GONAL-f (95%UI: € 5,167-€ 6,151), € 5,990 for Menopur (95%UI: € 5,498-€ 6,488) and 
€ 5,760 for Fostimon (95%UI: € 5,256-€ 6,246). The probability of a live birth was esti-
mated at 36.1% (95%UI: 27.4%-44.3%), 33.9% (95%UI: 26.2%-41.5%) and 34.1% (95%UI: 
25.9%-41.8%) for GONAL-f, Menopur and Fostimon respectively. Costs per live 
birth estimates are: € 15,674 (GONAL-f), € 16,878 (Fostimon) and € 17,636 (Menopur). 
Probabilistic sensitivity analysis indicates a probability of 72.5% that GONAL-f is 
cost-effective at a willingness-to-pay of € 20,000/live birth. Probabilistic results 
remained constant under several analyses. ConClusions: GONAL-f appears to 
study was set; methods employed; the inclusion of active comparators; and study 
endpoints. Data was extracted from each study using a predefined data extraction 
form. Results: Seventy studies met our inclusion criteria and were included in 
our dataset. Many of these analyses’ have concluded that PET is cost-effective; 38% 
of the cost-effectiveness analyses’ findings indicate ICERs less than $50,000 (2012 
USD). Growth in the cost-effectiveness literature for PET parallels growth of the 
cost-effectiveness literature more broadly with 35% of studies published since 2009. 
Across all years, a smaller proportion of studies examining PET emanated from the 
US than did cost-effectiveness analyses generally (29% vs. 42%). The majority of 
studies examined PET for oncological indications (n= 58; 83%). The most common 
analytical method employed was cost-effectiveness analysis, although two cost-
minimization studies were also identified. Studies typically compared PET to either 
x-ray computed tomographic imaging or usual care. Diagnostic accuracy was the 
most common unit of effectiveness reported. ConClusions: There is substantial 
literature evaluating the cost-effectiveness of PET across a range of indications. Most 
studies have examined diagnostic accuracy and not considered endpoints, such as 
how PET imaging influences clinical decision making or changes patient outcomes.
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objeCtives: Centralizing city-wide neonatal total parenteral nutrition (TPN) pro-
duction can reduce medication errors through standardized processes and order 
sets and pediatric pharmacist review. However, it is unclear if the benefits justify 
the cost. The purpose of this study was to determine the costs and benefits of cen-
tralizing city-wide multi-institution neonatal TPN production at a single pediatric 
institution. A second objective was to calculate the error reduction potential by 
centralizing neonatal TPN preparation. Methods: We performed a cost-benefit 
analysis of neonatal TPN preparation in a large metropolitan area, comparing the 
direct medical costs and benefits of centralized preparation at a large, nonprofit 
tertiary care pediatric hospital by pediatric pharmacists vs. decentralized prepara-
tion at multiple large, nonprofit tertiary care adult hospitals by staff pharmacists. 
Costs of TPN production and courier service were obtained from institution data. 
Medication error rates and costs of errors were obtained from the literature. We 
took the pediatric hospital perspective for a 5-year horizon. A 3% discount rate was 
used. Single-variable sensitivity analyses of medication error costs and error rates 
were performed to test the stability of the outcomes. Results: In 2013 adjusted 
dollars, total costs over 5 years for TPN centralization was $2,028,374 vs. $2,668,398 
for decentralization, a cost savings of $640,024. The primary benefit of TPN centrali-
zation was a decrease in the TPN error rate from 0.075% to 0.050%. Including both 
the costs of TPN production and the costs associated with TPN errors, the net cost 
of TPN centralization was $3,488,374 vs. $4,858,398 for decentralization, a net cost 
savings of $ 1,370,024. TPN centralization remained cost beneficial throughout the 
sensitivity analysis. ConClusions: Centralizing city-wide multi-institutional TPN 
production at a pediatric hospital has the potential to reduce medication errors and 
result in significant cost savings for all participating institutions.
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objeCtives: Cost utility analysis (CUA) is the technique of choice for decision 
making, yet the elicitation of utilities in children poses significant challenges. The 
objectives were to examine trends over time and to investigate sources for util-
ity weights used in pediatric CUA. Methods: The Pediatric Economic Database 
Evaluation (PEDE) Project http://pede.ccb.sickkids.ca/pede maintains a searchable 
database of pediatric economic evaluations published since 1980. Data on study 
characteristics are routinely collected from each citation, and health state descrip-
tions, utility weights, and utility sources are extracted for each CUA. Descriptive 
statistics were used to analyze study characteristics for all studies included in PEDE 
from 1980 to 2012. Results: The PEDE database includes 2,485 full comparative 
pediatric economic evaluations. Cost-effectiveness analyses (CEAs) represent 66% 
and CUAs 22% of studies. The proportion of CUAs has grown over time, from 0% in 
1980 to 54% in 2012, with an average annual growth rate of 30% since 2002. Before 
2004, CUAs constituted fewer than 15% of pediatric health economic evaluations. 
In 2009 CUAs overtook CEAs as the most common analytic technique. In contrast, 
cost-benefit analyses accounted for 27% of studies between 1980 and 1990 and 
this decreased to 2% in 2012. A total of 1,420 health states were described in 559 
CUAs published between 1980 and 2012, but only 60% included utility weights. The 
majority of these weights were derived from other published sources, including 
adult studies. ConClusions: The volume of pediatric CUAs has grown significantly 
since 1980 and CUAs now surpass CEAs as the most common technique for child 
health economic evaluation. However, few CUAs elicit utilities prospectively and 
rely instead on other published studies of unknown quality. Improved methods 
for eliciting utilities for child health states and the creation of a repository of valid 
utility weights will contribute to higher quality pediatric CUAs for decision-making.
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